LAKE FOREST, IL — May 17, 2002/ —
According to an article in this month’s publication of the journal Drugs, Prevacid® (lansoprazole), the #1 prescribed* proton pump inhibitor (PPI) in the United States, is a highly effective therapeutic option for acute treatment and chronic maintenance of erosive esophagitis (EE). Erosive esophagitis is a more severe form of gastroesophageal reflux disease (GERD). GERD may be characterized by frequent and persistent heartburn two or more days per week. Estimates suggest that approximately three percent of the U.S. population has GERD. “Continuous maintenance therapy is very important to a patient’s management of erosive esophagitis,” says Dr. James Freston, Professor of Medicine, University of Connecticut Health Center, and author of the paper.
“Without treatment, a majority of patients may experience esophagitis relapse within 12 months. This review of the data highlight’s Prevacid’s proven track record in EE.” The review, published this month in the journal Drugs, analyzes an extensive body of clinical data regarding Prevacid’s safety and efficacy in providing continuous relief of symptoms during chronic therapy and maintaining healing of erosive esophagitis. In addition, the publication outlines the clinical support for long-term management of erosive esophagitis.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!